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Cognitive deficits are the recognised symptoms of the dementias of later life. However, behavioural symptoms also 
contribute significantly to the problem and are often the main reason for a clinical consultation . The present study 
describes non - cognitive behavioural symptoms in 30 patients during various stages of dementia. Anxiety, depressive 
features, agitation, wandering and paranoid symptoms are the main features. The paper also discusses the usefulness 
and limitation of pharmacological treatment of these symptoms. 
M. he dementias of the later life have been es-
timated to become one of the major public health 
problems in the world (W.H.O., 1986). Epidemiologi-
cal studies have consistently shown a high prevalence 
of this disorder among people over 60 years: 5 to 8 
percent (Mortimer et al., 1981), andlife time cumula-
tive risk of becoming severely demented by the age of 
80 years has been computed to be between 15 to 20 % 
India, though still regarded as country of young 
population is going to have more and more people 
surviving beyond 60 years owing to improved nutrition 
and better health care in recent times. People above 60 
already constitute nearly 8 percent of the total popula-
tion in Indian and they are increasing with every suc-
cessive decade. Hence we are likely to see more and 
more of old age related problems. 
Psychopathology or clinical changes of demen-
tias usually fall in two categories: cognitive and be-
havioural. The cognitive changes arc well known and 
characteristic and are helpful in arriving at the diag-
nosis of dementia. The cognitive changes are related to 
declining intellectual abilities and lead to impairment 
in functions like new learning, attention and concentra-
tion, calculation abilities, memory, orientation, lan-
guage, day to day functioning and self-care. 
Behavioural changes are the other group of 
symptoms which are present from the beginning of the 
disease process or may make appearance during its 
course. Behavioural symptoms may produce per-
sonality changes, affective symptoms and even 
psvehotic symptoms like delusions and hallucinations. 
Unfortunately, there arc no effective treatments 
for most of the dementia cases except of those cases 
where dementia is of secondary rature consequent 
upon a treatable primary illness. Most of the cases of 
dementia in community or clinical settings are of 
primary degenerative kinds like Al/.heimcr's disease 
andmulti-infarct dementia. Inspitcofmany drugs being 
advocated for treating cognitive decline in elderly or 
dementia subjects, no significant improvement has 
been documented for majority of cognitive symptoms 
over short term or long term pharmacotherapy. 
Behavioural symptoms in dementia, though 
recognized for a long time, are again being studied 
systematically which because of their disturbing nature 
are a major cause of anxiety and concern for caregivers 
and are a frequent cause for hospitalization (Reisberg 
et al., 1987; Gustafson, 1975). Many investigators have 
attempted to study the treatability of these symptoms 
pharmacologically with variable response (Raskind et 
al., 1987). 
We are trying to study the clinical and psychoso-
cial aspects of dementia systematically and the present 
paper attempts to discuss the behavioural 
symptomatology of dementia in Indian setting. 
MATERIAL AND METHOD 
Included in the study are 30 patients (12 males and 
18 females ) with mean age of 63.8 + 5.4 years (range 
55-77 years) drawn from the Neuro-Sciences Centre of 
the All India Institute of Medical Sciences, New Delhi. 
All patients met DSM-III-R criteria for demen-
tia. All patients were living in the community with their 
family members who were primarily responsible for 
their looking after and wellbeing. Detailed socio-
demographic characteristics are presented in Table 1. 
The clinical evaluation of these patients in-
cluded detailed medical, psychiatric and neurological 
histories and examination. Relevant investigations like 
routine haemogram and blood chemistry, urinalysis, 
radiological examination of chest and skull, electroen-
cephalogram, CT scans were done wherever necessary. 
Detailed Information about the patients' symptoms and 
other clinical changes was obtained from the patients 
and their close relatives. Patients were also ad-
ministered Global Deterioration Scale (GDS) (Reis-
berg et al., 1982) for clinical staging of the dementia. 
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berg ei al., 1982) for clinical staging of the dementia. 
GDS is an instrument for staging of primary degenera-
tive dementia and is divided into seven rating points 
corresponding to seven distinct clinically identifiable 
stages of the disease process: normal, forgetfulness, 
early confusional, late confusional, early dementia, 
middle dementia and late dementia. Behavioural 
symptoms were recorded during intake of history of 
illness and mental state examination and special efforts 
were made to record presence or absence of certain 
behavioural changes which are often reported in the 
literature on dementia viz., paraniod delusions, depres-
sive symptoms, wandering, agitation etc. 
Table 1. Subjects characteristics (N = 30) 
Sex 
Age (in years) 
Marital status 
Employment 
Male = 12 
Female = 18 
Range : 55 - 77 
Mean : 63.8 ± 5.4 
Married and living with spouse 
Widowed 
Single, never married 
24 
5 
1-
Full time employment 
Part-time employment 
Retired/not working 
Premature retirement 
Living arrangement 
Nuclear family 
Joint family 
None in any institution 
:6 
(all males) 
:6 
14 
4 
= 7 
= 23 
RESULTS 
O,  "ut of the 30 patients, five patients had as-
sociated hypertension and were receiving beta-block-
ers for its control. Two of these 5 patients had diabetes 
mellitus too which was under control with help of oral 
hypoglycemic agents. None of these 5 patients ever had 
any history of coma, hypertensive crisis or diabetic 
ketosis. Two of these patients had past history of stroke 
with complete recovery. Detailed history, examination 
and investigations failed to reveal any other systemic or 
intracranial pathology and thus ruled out any case of 
secondary dementia. Twelve patients belonged to GDS 
stages 3 and 4 and could be classified to have low 
severity of dementia, while severity was high in 14 
patients (stage 5 and above). Four patients belonged to 
stage 2 (forgetfulness) which denotes very mild cogni-
tive decline. Behavioural symptoms in varying intensity 
were seen in all patients. These symptoms and their 
frequencies are given in table 2. It was observed that 
patients with mild cognitive decline tended to have 
anxiety and depressive symptoms; patients with 
moderate intensity of dementia had depressive and 
paranoid symptoms, while paranoid and motor 
symptoms predominated in severe cases. However, 
there was considerable overlap of symptoms among 
various stages of dementia based on severity. Number 
of symptoms per patient varied from 2 to 9 with a mean 
of 3.7. 
Table 2. Nature and frequency of behavioural 
symptoms (N=30) 
Symptom 
People are stealing thing 
One's house is not one's home 
Delusion of abondonment 
Delusion of infidelity 
Suspiciousness 
Visual hallucination 
Verbal outbursts 
Physical threats 
Agitatipn 
Wandering 
Purposeless activity 
Inappropriate activity 
Day night disturbance 
Depressed mood 
Anxiety 
Excessive eating 
N 
8 
3' 
3 
3 
10 
6 
12 
3 
14 
7 
13 
6 
12 
10 
6 
4 
% 
27 
10 
10 
10 
•*. 33 - • 
20 
40 
10 
146 
23 
43 
20 
40 
33 
20 
13 
*• 
Many of these patients received psychotropic 
drugs for the management of their behavioural 
symptoms during follow up. Drugs used were: 
diazepam or nitrazepam (5-10 mg/day), imipramine 38 S.K. KHANDELWAL, et ai 
(50- 75 mg/day) or chlorpromazine (75-150 mg/day). 
Care was taken to give minimum possible dose of a drug 
with a regular watch for any side effects. Drugs like 
cerebral vasodilators, cerebral activators or stimulants 
were not used in any case. Duration of drug usage was 
2 weeks - 12 months for benzodiazepines, 6 weeks - 9 
months for imipramine and 4 weeks - 6 months for 
chlorpromazine. No patient developed any significant 
side effects with these small doses. In many cases, drugs 
were used only intermittently. Behavioural symptoms 
which responded to drug treatment are listed in Table 
3. However, no objective prctrealment and posttreal-
ment ratings are available for the present study. 
Table 3. Psychotropic drugs and the target symptoms 
Drug 
Benzodiazepines 
Anlideprcsscnt 
Phcothiazincs 
Target symptoms 
Anxiety, agitation, insortiania, 
purposeless activity 
Depressive features 
Paranoid symptoms, vftrbal 
outbursts, agitation 
et ai (1987) also found delusions and behavioural 
symptoms in nearly half of their patients of both demen-
tias though perceptual disturbances were uncommon. 
Depressive symptoms were evident on Hamilton 
Rating scale for Depression but did not satisfy DSM-III 
criteria. Burns et ai (1990) in a large sample of 178 
subjects with Alzheimer's disease found delusions 
(16%), hallucinations (17%), depression (24%) and 
aggression (21%). Berrios and Brook (1985) inves-
tigated 100 patients of dementia and found hallucina-
tion, delusions and other psychopathology in a large 
number of them. Rubin et ai (1989) reported be-
havioural symptoms in 84% of subjects with mild 
dementia. In our patients of mixed etiology, be-
havioural symptom of verying intensity could be 
detected in practically all cases and number of 
symptoms per patient varied from a low of 2 to a high 
of 9 from the list of symptoms given in Table 2. 
Benzodiazepines Anxiety, agitation, insortiania, 
purposeless activity 
Anlideprcsscnt Depressive features 
Phcothiazincs Paranoid symptoms, vftrbal 
outbursts, agitation 
DISCUSSION 
JL he paper provides preliminary information 
about the prevalence and nature of behavioural 
symptoms in dementia m hospital setting. Our sample 
of 30 patients consists of degenerative dementias 
(Alzheimer's and multi-infarct) and no case of secon-
dary dementia. Considering the scope of paper, we 
have not further divided the sample into subgroups. 
Cognitive disturbances in dementia have been studied 
for a long time; infact, these deficits arc the very basis 
for the diagnosis of dementia. Lately, many workers 
have been attempting to study behavioural symptoms in 
various stages of dementia, particularly, of Alzheimer 
type (Reisbcrgef a/., 1987; Rubin et al., 1989; Cummings 
et ai, 1987; Burns*/ al., 1990). Diagnostic and Statistical 
Manual of Mental Disorder, 3rd edition revised (APA, 
1987) also gives a detailed account of such associated 
symptoms, like anxicty.depression, excessive orderli-
ness, social withdrawal, paranoid ideation, false ac-
cusation and verbal or physical attacks. As much as 
60-84% of patients of Alzheimer's Disease had sig-
nificant behavioural symptoms in above studies. Rcis-
bcrg et al. (1987) found 58% patients of Alzheimer's 
dementia having significant behavioural symptomatol-
ogy consisting most commonly of delusions, nonspecific 
agitation and diurnal rhythm disturbances. Cummings 
Delusions and paranoid symptoms were present 
in 48% of cases, hallucinations in 20%, depressed mood 
in 33% and aggression in 40% cases. Though from these 
data one cannot draw any conclusion regarding in-
cidence or prevalence of behavioural symptoms in 
dementia in general population, yet such a study 
provides useful information about nature and progress 
of such symptoms. So far, the management of dementia 
has remained very pessimistic as no worthwhile phar-
macological intervention is available for cognitive 
deficits. Most of the time, clinicians have intervened 
only to make a diagnosis without making any effort Jor 
encouraging follow-up or looking at the psychosocial 
aspects of the problem. Even if a family has accepted 
the irreversible cognitive deficits of a dementia patient, 
it may still find behavioural symptoms troublesome and 
would like to sec a clinician for such complaints. 
The nature of behavioural symptoms usually 
depends upon the staging or severity of dementia 
process. Patients with questionable or very mild 
dementia usually have personality changes like passive 
changes (inactive, less cheerful, less responsive), agita-
tion (irritability, increased motor responses) and self 
ccntrcdness. More patients with mild dementia 
demonstrate depressive symptoms like low levels of 
interest and concentration, and psychomotor retarda-
tion. In a long follow up study of Alzheimer's disease it 
has been seen that such changes arc probably a result 
of the process of disease and not a concurrent depres-
sion (Kncsevich, 1983). 
j Psychotic symptoms like suspiciousness, 
I delusions and hallucinations arc most obvious during 
the moderate stage and usually do not appear before 
the mild degree of illness Such psychotic symptoms are 
Anxiety, agitation, insortiania, 
purposeless activity 
Depressive features 
Paranoid symptoms, vftrbal 
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usually a result of cognitive deficit as a patient with 
memory deficit may misplace things and then complain 
that "people are stealing things" (Reisbergef a/., 1987). 
In severe degree, patients usually have purpose less 
activity and wandering before losing control of most of 
their mental functions. Our results also tended to go in 
this direction. Now we plan to study the appearance and 
development of such symptoms in a longitudinal follow 
up of subjects with questionable or very mild dementia 
over a period of time to study their natural history. 
Pharmacological treatment of non-cognitive, 
behavioural symptoms has remained controversial. As 
early as 1955, Seager evaluated chlorpromazine on the 
behaviour of 29 elderly psychotic women, Cognitive 
symptoms of dementia did not improve with 
chlorpromazine, but there was a global improvement in 
disturbed behaviour of these women. Sugerman et al. 
(1964) tried haloperidol 4.5 mg/day and placebo in 18 
dementia patients, many of whom were agitated, over-
active and hostile. Haloperidol was found to be supe-
rior when symptoms such as hallucination, restlessness, 
overactivity and uncooperativeness were present. Coc-
caro et al. (1990) studied 59 elderly dementia patients 
in an 8- week randomized, double-blind comparison 
trial of haloperidol, oxazepam and diphenhydramine. 
All three drugs demonstrated modest but sig-
nificant efficacy in agitated behaviour and activities of 
daily living. The absolute magnitude of improvement 
was greater for haloperidol and diphenhydramine than 
for oxazepam, but differences among groups did not 
approach statistical significance. Petrie el al. (1982) 
evaluated haloperidol (4.6 mg/day), loxapine (22 
mg/day) and placebo in 64 dementia patients of primary 
degenerative dementia and multi-infarct dementia. Ac-
tive medication was significantly more effective than 
placebo on BPRS items like suspiciousness, hal-
lucinatory behaviour, excitement, hostility and un-
cooperativeness. However only 32% of 
loxapine-treated patients, 35% haloperidol-treated 
patients and 9% of placebo-treated patients were 
globally rated as moderately or markedly improved. 
This fact is important since these percentages are much 
lower than those usually reported in younger non-de-
mented psychotic patients. In another similarly 
designed study, Barnes et al. (1982) evaluated 
thioridazine (mean dose, 62.5 mg/day), loxapine (mean 
dose, 10.5 mg/day) and placebo and obtained similar 
results. It appears that target symptoms such as agita-
tion, hyperactivity, hallucinations, delusions and 
paranoid ideation must be present if antipsychotic 
drugs are to be effective. Though ours is not a double 
blind study, it does tell us about the nature of be-
havioural symptoms in dementia patients, and useful-
ness of some drugs in certain target symptoms (Tabic 
3). 
Since we used drugs in small quantities and that 
too intermittently, we did not encounter any 
problematic side effects. However, one must be 
cautious of short-term and long- term side effects of 
psychotropic drugs, especially neuroleptics, in elderly 
subjects who may be more prone to developing conven-
tional side effects. Drugs may also adversely affect their 
already compromised cognitive state. Development of 
tardive dyskinesia would remain a major concern while 
using neuroleptics in elderly individuals. Akalhisia is 
very common and dysphoric effects of akathisia are very 
troublesome, yet difficult to diagnose. Drugs may also 
lead to further behavioural disruption when are indis-
criminately prescribed for non-specific aggressive be-
haviour. All such limitations of drug-therapy are 
essential to be kept in mind. 
It appears that behavioural disorder in elderly 
demented subjects demands careful evaluation. Be-
havioural symptoms may be caused by a variety of 
physical illnesses, medications and environmental and 
psychosocial factors. Since therapeutic efficacy of 
psychotropic medication is limited, it is especially im-
portant to look for above factors. Proper management 
of physical illnesses and offending medications may 
alleviate the problem significantly. Similarly, one must 
strive to search for possible social and environmental 
solutions for behavioural disturbances in this popula-
tion. 
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